Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores by Collins, Gary S et al.
Predicting risk of osteoporotic and hip fracture in the
United Kingdom: prospective independent and external
validation of QFractureScores
Gary S Collins senior medical statistician, Susan Mallett senior medical statistician, Douglas G
Altman director, professor of statistics in medicine
Centre for Statistics in Medicine, Wolfson College Annexe, University of Oxford, Oxford OX2 6UD, UK
Abstract
Objective To evaluate the performance of the QFractureScores for
predicting the 10 year risk of osteoporotic and hip fractures in an
independent UK cohort of patients from general practice records.
Design Prospective cohort study.
Setting 364 UK general practices contributing to The Health
Improvement Network (THIN) database.
Participants 2.2 million adults registered with a general practice between
27 June 1994 and 30 June 2008, aged 30-85 (13 million person years),
with 25 208 osteoporotic fractures and 12 188 hip fractures.
Main outcome measures First (incident) diagnosis of osteoporotic
fracture (vertebra, distal radius, or hip) and incident hip fracture recorded
in general practice records.
Results Results from this independent and external validation of
QFractureScores indicated good performance data for both osteoporotic
and hip fracture end points. Discrimination and calibration statistics were
comparable to those reported in the internal validation of
QFractureScores. The hip fracture score had better performance data
for both women and men. It explained 63% of the variation in women
and 60% of the variation in men, with areas under the receiver operating
characteristic curve of 0.89 and 0.86, respectively. The risk score for
osteoporotic fracture explained 49% of the variation in women and 38%
of the variation in men, with corresponding areas under the receiver
operating characteristic curve of 0.82 and 0.74. QFractureScores were
well calibrated, with predicted risks closely matching those across all
10ths of risk and for all age groups.
Conclusion QFractureScores are useful tools for predicting the 10 year
risk of osteoporotic and hip fractures in patients in the United Kingdom.
Introduction
The World Health Organization defined osteoporosis as a
progressivesystemic,skeletaldiseasecharacterisedbylowbone
mass and micro-architectural deterioration of bone tissue with
a consequent increase in bone fragility and susceptibility to
fracture.
1 In 2000 an estimated 9 million incident cases of
osteoporotic fractures occurred worldwide, comprising 1.6
million hip fractures, 1.7 million fractures of the forearm, and
1.4 million vertebral fractures. The annual costs of health and
social care for fractures in the United Kingdom are estimated
to be £1.8bn (€2bn; $3bn).
2
Identifying those at an increased risk of fracture and who might
benefit from a therapeutic or preventive intervention is
important. QFractureScores are sex specific multivariable risk
scores that have recently been developed to predict the 10 year
risk of both osteoporotic fracture (vertebra, distal radius, or hip)
and hip fracture.
3
The risk scores were developed and validated on a large cohort
of patients (3.6 million) from the QResearch (www.qresearch.
org)database;twothirdsofthecohortwererandomlyallocated
to model development and one third to model validation.
QResearch is a large database comprising over 12 million
anonymised health records from 602 practices throughout the
United Kingdom that use the Egton Medical Information
Systems (EMIS) computer system (used in 59% of general
practices in England). QFractureScores were developed on 2.4
million patients aged between 30 and 85 years contributing 16
million person years of observation, with 32 284 incident
diagnoses of osteoporotic fracture, and 14 726 hip fractures,
recorded between 1 January 1993 and 30 June 2008.
QFractureScoreswerederivedusingaCoxproportionalhazards
model. Fractional polynomials were used to model non-linear
risk relations with continuous risk factors, and the presence of
interactionsbetweenriskfactorswastested.
4Multipleimputation
wasusedtoreplacemissingvaluesforkeyriskfactors(smoking
status, alcohol consumption, and body mass index) to reduce
thebiasesthatcanoccurinacompletecaseanalysis.
5 6Thefinal
prediction model included 17 risk factor terms for women and
12 for men (box). Open source codes to calculate the
QFractureScoresareavailablefromwww.qfracture.orgreleased
under the GNU lesser general public licence, version 3. The
performance of the QFractureScores was assessed on an
additional 1.3 million patients from the QResearch database
with 18 471 incident osteoporotic fractures and 7162 incident
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RESEARCHhip fractures and showed favourable performance when
compared with the FRAX (fracture risk assessment) score.
7
The development of the model and initial internal validation
study were both carried out using random samples of data from
the same population. External validation is also important to
evaluate the model’s performance more widely.
8 9 We
independently evaluated the performance of QFractureScores
on a separate large dataset of general practice records in the
United Kingdom.
Methods
Study participants were patients registered between 27 June
1994 and 30 June 2008 with records on the THIN database
(www.thin-uk.com). This database comprises the records of
general practices that use the INPS Vision system (In Practice
Systems, London); currently 20% of UK general practices.
Patients were eligible if they were aged between 30 and 85
years, had no previously recorded fracture (hip, distal radius,
or vertebra), were permanent residents in the United Kingdom,
and had no interrupted periods of registration with a practice.
Primary outcomes
The two primary outcomes were first (incident) diagnosis of an
osteoporoticfracture(hip,distalradius,orvertebra)asrecorded
on the general practice computer records (THIN), and incident
diagnosis of hip fracture.
Statistical analysis
We determined an entry date for each patient, which was the
latest of the date of their 30th birthday, date of registration with
the practice, date on which the practice computer system was
installed plus one year, or the beginning of the study period (27
June 1994). Patients were included in the analysis only once
theyhadaminimumofoneyear’scompletedataintheirmedical
record. Observation time was calculated from the entry date to
an exit date, which was defined as the earliest date of recorded
fracture, date of death, date of deregistration with the practice,
date of last upload of computerised data, or the study end date
(30 June 2008).
Smoking status (when recorded) was derived from two risk
factors: whether the patient was a non-smoker, former smoker,
or current smoker, and the number of cigarettes
smoked—categorised as light (<10 cigarettes/day), moderate
(10-19 cigarettes/day), or heavy (≥20 cigarettes/day). These
two risk factors were then combined into five categories:
non-smoker, former smoker, light smoker, moderate smoker,
and heavy smoker.
UsingQFractureScoreswecalculatedthe10yearestimatedrisk
of fracture (osteoporotic and hip) for every patient in the THIN
cohort. We used the Kaplan-Meier method to obtain observed
10 year fracture risks. To replace missing values for smoking
status, number of cigarettes smoked, alcohol consumption, and
body mass index we used multiple imputation using all
predictors plus the outcome variable. This involves creating
multiple copies of the data and imputing the missing values
with sensible values randomly selected from their predicted
distribution. We generated five imputed datasets and combined
the results from analyses on each of the imputed datasets using
Rubin’srulestoproduceestimatesandconfidenceintervalsthat
incorporate the uncertainty of imputed values.
10
PredictiveperformanceofQFractureScoresfortheTHINcohort
was assessed by examining measures of calibration and
discrimination. Calibration refers to how closely the predicted
10 year risk of fracture agrees with the observed 10 year risk
of fracture. We assessed this for each 10th of predicted risk,
ensuring 10 equally sized groups, and for each five year age
band by calculating the ratio of predicted to observed fracture
risk separately for men and for women. We assessed the
calibration of the risk score predictions by plotting observed
proportions versus predicted probabilities. The Brier score for
censored survival data was also calculated, which is a measure
of accuracy and is the average squared deviation between
predicted and observed risk; a lower score represents greater
accuracy.
11
Discrimination is the ability of the risk score to differentiate
betweenthosepatientswhodoandthosewhodonotexperience
a fracture event during the study. This measure is quantified by
calculating the area under the receiver operating characteristic
curvestatistic;avalueof0.5representschanceand1represents
perfect discrimination. We also calculated the D statistic
12 and
R
2statistic,
13whicharemeasuresofdiscriminationandexplained
variation, respectively, and are tailored towards censored
survival data.
All statistical analyses were carried out in R (version 2.11.1)
14
and the imputation by chained equations (ICE) procedure in
Stata (version 11).
15
Results
Between 27 June 1994 and 30 June 2008, 2 244 636 eligible
patientsfrom364generalpracticesintheUnitedKingdomwere
registered in the THIN database. For the osteoporotic fracture
end point, 2 209 451 patients (50.6% women) were eligible for
analysis (27 551 had a recorded fracture before 27 June 1994
and were excluded) contributing 12 784 326 person years of
observation, of which there were 25 208 incident cases of
osteoporotic fracture. For the hip fracture end point, 2 244 636
patients were eligible for analysis (5202 had a recorded hip
fracture before 27 June 1994 and were excluded) contributing
13 053 891 person years of observation, of which there were
12 188 incident cases of hip fracture. The median follow-up for
theosteoporoticfractureendpointwas5.98(interquartilerange
2.61-8.50) years and for the hip fracture end point was 6.03
(2.62-8.50) years. In total, 319 991 patients (14.5%) were
followed up for 10 years or more for the osteoporotic end point
and 329 571 patients (14.7%) for the hip fracture end point.
The 10 year observed risk of osteoporotic fracture in women
(19 055 incident osteoporotic fractures) aged between 30 and
85 was 3.04% (95% confidence interval 2.99% to 3.09%) and
inmen(6153incidentosteoporoticfractures)was1.04%(1.01%
to 1.07%). The 10 year observed risk of hip fracture in women
(9165incidenthipfractures)agedbetween30and85was1.48%
(1.44% to 1.51%) and in men (3023 incident hip fractures) was
0.52% (0.50% to 0.54%). Table 1 details the characteristics of
the patients in the THIN cohort.
Complete data on smoking status, smoking category, alcohol
consumption, and body mass index were available for 44.5%
of women (n=506 081) and 31.8% of men (n=352 380). Most
patients (n=1 693 039; 75.4%) had no or only one missing risk
factor (table 2). Missing data were noticeably high for alcohol
consumption (45.0% for women and 60.7% for men). For other
risk factors 17.6% of women and 24.4% of men had missing
data on body mass index, 13.5% and 12.4% on smoking status,
and 6.1% and 10.8% for number of cigarettes smoked.
Table 3 shows the incidence rates (per 1000 person years) for
fracturebyageandsexintheTHINcohort.Womenexperienced
19 055 fractures during 6 493 740 person years of follow-up:
incidencerate2.93(95%confidenceinterval2.89to2.98).Men
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Women and men
• Age (continuous)
• Body mass index (continuous)
• Smoking status (non-smoker, former smoker, light smoker (<10 cigarettes/day), moderate smoker (10-19 cigarettes/day),
heavy smoker (≥20 cigarettes/day)
• Recorded alcohol use (none, trivial <1 unit/day, light 1 or 2 units/day, medium 3-6 units/day, heavy 7-9 units/day,
very heavy >9 units/day)
• Diagnosis of rheumatoid arthritis (yes/no)
• Diagnosis of cardiovascular disease (yes/no)
• Diagnosis of type 2 diabetes (yes/no)
• Diagnosis of asthma (yes/no)
• At least two prescriptions for tricyclic antidepressants in the six months before baseline (yes/no)
• At least two prescriptions for corticosteroids in the six months before baseline (yes/no)
• History of falls (yes/no)
• Diagnosis of chronic liver disease (yes/no)
Women only
• Parental history of osteoporosis (yes/no)
• Diagnosis of gastrointestinal malabsorption (yes/no)
• Diagnosis of other endocrine symptoms (yes/no)
• At least two prescriptions of hormone replacement therapy (yes/no)
• Menopausal symptoms (yes/no)
experienced6153osteoporoticfracturesduring6290586person
years of follow-up: incidence rate 0.98 (0.95 to 1.00). The rates
of osteoporotic fracture were highest in those aged 80 to 85
yearsatbaseline:incidencerateinwomen17.7(17.14to18.28)
and in men 7.01 (6.54 to 7.51). Hip fractures accounted for
48.1% of fractures in women and 49.1% in men. Overall, 9165
hip fractures were recorded for women during the 6 673 972
person years of follow-up, giving an overall incidence rate of
1.37(1.35to1.40),whereasformen,3023incidenthipfractures
occurred during 6 379 919 person years of follow-up, giving an
incident rate of 0.47 (0.46 to 0.49). Among those aged 80 to 85
years the incidence of hip fracture in women was 12.47 (12.02
to 12.94) and in men was 5.42 (5.01 to 5.86).
Table 4 presents the performance data on discrimination and
calibrationfortheQFractureScoresintheTHINcohortalongside
those previously reported in the internal validation using the
QResearch cohort.
3 The R
2 statistic (percentage of explained
variation) was about 4% higher for the osteoporotic fracture
score in women and 8% higher in men compared with the
internalvalidationperformancedata.Forthehipfracturescore,
the R
2 statistic was marginally lower for both women (1%) and
men (3%) in the THIN cohort compared with the internal
validation.TheDstatisticwasnoticeablyhigherforhipfracture
in both women and men (2.66 and 2.53) than for osteoporotic
fracture (2.02 and 1.60). The D statistics of QFractureScores
for osteoporotic fracture were higher in the external validation
than in the internal validation. Values for the area under the
receiver operating characteristic curve were higher for
osteoporotic fracture in the THIN cohort in both women and
men(0.816and0.739)thanintheinternalvalidation(0.788and
0.688). Values for the area under the receiver operating
characteristic curve for hip fracture alone were higher than for
osteoporoticfracture,whereasvalueswerecomparabletothose
obtained in the internal validation. The Brier score (adjusted
for censoring), a measure of prediction accuracy, was better for
hip fracture than for osteoporotic fracture.
Figures 1 and 2 present the calibrations of QFractureScores for
men and women by 10th of risk for both the THIN cohort
(external validation) and the QResearch cohort (internal
validation). Model calibration was good, with close agreement
between predicted and observed risk of osteoporotic and hip
fractures across all 10ths of risk, with no discernible
over-predictionorunder-prediction.Similarly,figure3displays
the calibration of QFractureScores for men and women by age
group.Agreementbetweenpredictedandobservedfracturerisks
was close across all age groups.
Discussion
QFractureScores are four new risk scores for predicting the 10
year risk of osteoporotic and hip fracture separately in men and
women, developed and internally validated on the large UK
primary care electronic QResearch database.
3 The database
comprised 3.7 million patients registered between 1 January
1993 and 30 June 2008, contributing 50 755 osteoporotic
fractures, 19 531 hip fractures, and 25 million person years of
observation using the EMIS computer system.
QFractureScores were designed to be based on risk factors that
are readily available and recorded in patients’ health records or
which patients themselves are likely to know. Other risk scores
for predicting osteoporotic fracture have included clinical ones
suchaslossofbonemineraldensity,asmeasuredbydualenergy
x ray absorptiometry.
7 16 The rationale for excluding laboratory
tests or clinical measurements in QFractureScores was to make
the score readily available and cost effective so that it could be
easily implemented in routine clinical practice and national
screening initiatives. All the variables in the QFractureScores
will be known to the patient or collected as part of routine
clinical practice and recorded within the patients’ healthcare
record. Thus QFractureScores can be applied in primary care
to identify patients who are at high risk and would benefit from
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identify those at an increased risk.
WHOhasrecentlydevelopedariskpredictionmodel,theFRAX
(fractureriskassessment)instrument,topredictindividualrisks
offracture.
7FRAXhasbeenincorporatedintoclinicalguidelines
in the United Kingdom and United States
17-19 and uses
information on age, sex, height, body mass index, previous
fracture, family history of fracture, glucocorticoid use, current
smokingstatus,alcoholconsumption,rheumatoidarthritis,other
secondarycausesofosteoporosis,and,ifavailable,bonemineral
density of the femoral neck. The details and source code for the
calculation of an individual’s risk using FRAX has to date not
been published or released for independent evaluation. We
sought to compare QFractureScores against FRAX for the hip
fracture end point but our requests for an independent head to
headcomparisonwerenottakenupbythedevelopersofFRAX.
AlthoughthedevelopmentandintendeduseofQFractureScores
were for the United Kingdom, the risk factors in both the
osteoporoticandthehipfracturemodelsincludenoUKspecific
terms (such as the Townsend deprivation score as used in other
QResearchriskscoresorethnicity).Thereisthusnoreasonwhy
the QFractureScores could not be used outside the United
Kingdom;however,theperformanceofthemodelswouldneed
to be established before use in a different population.
OurindependentevaluationofQFractureScoreswascarriedout
onthelargeseparatedatabase(THIN)basedongeneralpractices
recording clinical data using the INPS Vision system, which is
used in 20% of UK general practices. The dataset comprised
2.2 million patients registered between 27 June 1994 and 30
June2008,contributing13millionpersonyearsofobservation.
The performance data presented in this article on the THIN
cohort provide strong evidence to support the external validity
of QFractureScores in predicting 10 year risk of osteoporotic
or hip fracture, with comparable performance to that observed
intheinternalvalidationdata.QFractureScoresforosteoporotic
and hip fracture end points in both women and men were well
calibrated in this large cohort, with good agreement between
predicted and observed risks. Discriminant ability in both the
internal validation and the external validation are impressive,
with values for the area under the receiver operating
characteristic curve exceeding 0.8 for women and 0.73 for
osteoporotic fracture in men and 0.86 for hip fracture in men.
To date, the development, internal validation, and our external
validation of QFractureScores have used 5.9 million patients.
These patients have contributed 38 million person years of
observation and 75 963 new cases of osteoporotic fractures and
31 719 of hip fractures during the observation periods. Such
data have been used to develop and evaluate four risk scores to
predictthe10yearriskofosteoporoticandhipfractureinadults
aged 30 to 85.
Conclusions
In this study, we have provided an independent and external
validation of the QFractureScores risk score on a large cohort
of patients in the United Kingdom. We have assessed the
performance of QFractureScores against the performance data
fromtheinternalvalidationofQFractureScoreswithcomparable
results and shown good evidence to confirm predictive power
of the risk scores without the need for recalibration.
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RESEARCHWhat is already known on this topic
International guidelines propose a targeted approach based on a 10 year absolute fracture risk for identifying high risk
patients who may benefit from interventions
QFractureScores were developed and internally validated using a large cohort of UK patients and published in 2009
Risk prediction models need to be independently and externally validated to objectively evaluate performance
What this study adds
Results from this independent and external validation of QFractureScores indicated good performance data for both
osteoporotic and hip fracture end points
The performance data for both risk prediction models, especially for hip fracture score, suggest that the QFractureScores
could be useful in identifying patients in the UK who are at increased risk of osteoporotic fracture who could benefit
from interventions
Tables
Table 1| Characteristics of patients aged 30 to 85 years in THIN database. Values are numbers (percentages) unless stated otherwise
External validation cohort (THIN) Derivation cohort (QResearch)
Characteristics Men (n=1 108 219) Women (n=1 136 417) Men (n=1 174 232) Women (n=1 183 663)
47 (37-59) 48 (37-62) 46 (37-59) 48 (37-62) Median (interquartile range) age (years)
Alcohol consumption:
132 872 (12.0) 243 624 (21.4) 140 925 (12.0) 275 984 (23.3) None
168 374 (15.2) 288 754 (25.4) 226 118 (19.3) 341 295 (28.8) Trivial <1 unit/day
72 962 (6.6) 71 616 (6.3) 234 460 (20.0) 162 433 (13.7) Light 1 or 2 units/day
48 270 (4.4) 17 911 (1.6) 96 202 (8.2) 19 455 (1.6) Moderate 3-6 units/day
7986 (0.7) 1558 (0.1) 11 006 (0.9) 1208 (0.1) Heavy 7-9 units/day
5046 (0.5) 1178 (0.1) 8877 (0.8) 1231 (0.1) Very heavy >9 units/day
672 709 (60.7) 511 776 (45.0) 456 616 (38.9) 382 063 (32.4) Not recorded
Body mass index:
26.63 (4.1) 26.15 (5.0) 26.43 (4.1) 25.88 (4.9) Mean (SD)
270 900 (24.4) 200 192 (17.6) 392 613 (33.4) 299 140 (25.3) Not recorded
Smoking status:
401 760 (36.3) 530 062 (46.6) 462 344 (38.9) 630 470 (53.3) Non-smoker
158 600 (14.3) 125 816 (11.1) 173 503 (14.6) 139 496 (11.8) Former smoker
Current smoker:
68 077 (6.1) 70 741 (6.2) 69 504 (5.9) 51 945 (4.4) Light (<10 cigarettes/day)
104 844 (9.5) 109 052 (9.6) 146 959 (12.4) 131 563 (11.1) Moderate (10-19 cigarettes/day)
117 567 (10.6) 77 828 (6.9) 77 147 (6.5) 54 489 (4.6) Heavy (≥20 cigarettes/day)
137 617 (12.4) 153 448 (13.5) 244 775 (20.9) 175 700 (14.8) Amount not recorded
119 754 (10.8) 69 470 (6.1) 244 775 (20.9) 175 700 (14.8) Not recorded
5260 (0.5) 12 340 (1.1) 3903 (0.3) 9459 (0.8) Rheumatoid arthritis
76 585 (6.9) 54 520 (4.8) 62 265 (5.2) 41 842 (3.5) Cardiovascular disease
35 157 (3.2) 28 039 (2.5) 27 637 (2.3) 22 645 (1.9) Type 2 diabetes
78 079 (7.1) 97 177 (8.6) 55 888 (4.7) 66 892 (5.7) Asthma
23 048 (2.1) 59 803 (5.3) 14 646 (1.2) 46 054 (3.9) Current tricyclic antidepressants
23 686 (2.1) 36 752 (3.2) 11 569 (1.0) 20 005 (1.7) Current corticosteroids
14 911 (1.4) 29 106 (2.6) 4676 (0.4) 8801 (0.7) History of falls
2586 (0.2) 1892 (0.2) 2133 (0.2) 1563 (0.1) Chronic liver disease
5047 (0.5) 6388 (0.6) 4851 (0.4) 5970 (0.5) Gastrointestinal malabsorption
2124 (0.2) 9665 (0.9) 1886 (0.2) 8615 (0.7) Other endocrine conditions
— 58 507 (5.2) — 25 683 (2.2) Menopausal conditions
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RESEARCHTable 1 (continued)
External validation cohort (THIN) Derivation cohort (QResearch)
Characteristics Men (n=1 108 219) Women (n=1 136 417) Men (n=1 174 232) Women (n=1 183 663)
1.04 (1.01 to 1.07) 3.04 (2.99 to 3.09) Not reported Not reported 10 year osteoporotic fracture risk (95% CI)
0.52 (0.50 to 0.54) 1.48 (1.44 to 1.51) Not reported Not reported 10 year hip fracture risk (95% CI)
Country:
956 465 (86.3) 980 465 (86.3) Not reported Not reported England:
29 428 (2.7) 31 478 (2.8) Not reported Not reported Northern Ireland
59 754 (5.4) 61 563 (5.4) Not reported Not reported Scotland
62 572 (5.7) 62 911 (5.5) Not reported Not reported Wales
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No (%) of men (n=1 108 219) No (%) of women (n=1 136 417) No of risk factors not recorded (per patient)
352 380 (31.8) 506 081 (44.5) 0 (no missing data)
435 719 (39.3) 398 859 (35.1) 1
186 061 (16.8) 151 328 (13.3) 2
23 343 (2.1) 17 755 (1.6) 3
110 716 (10.0) 62 394 (5.5) 4
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RESEARCHTable 3| Incidence rates of osteoporotic fracture (distal radius, hip, or vertebra) and hip fracture per 1000 person years in THIN cohort by
age at baseline in men and women
Hip fractures Osteoporotic fractures
Age (years)
Rate/1000 person years (95%
CI)
No of
fractures
Person years of
observation
Rate/1000 person years (95%
CI) No of fractures
Person years of
observation
Women:
0.03 (0.02 to 0.05) 31 925 879 0.42 (0.38 to 0.46) 386 917 642 30-34
0.04 (0.03 to 0.06) 38 895 173 0.44 (0.40 to 0.49) 393 886 876 35-39
0.08 (0.06 to 0.10) 60 782 832 0.60 (0.55 to 0.66) 468 774 263 40-44
0.18 (0.15 to 0.21) 132 736 908 0.96 (0.89 to 1.04) 701 727 432 45-49
0.31 (0.27 to 0.35) 226 726 914 1.57 (1.48 to 1.66) 1119 714 507 50-54
0.56 (0.50 to 0.62) 345 615 661 2.22 (2.10 to 2.34) 1331 600 457 55-59
1.01 (0.93 to 1.10) 539 533 233 3.54 (3.37 to 3.70) 1815 513 369 60-64
1.97 (1.85 to 2.10) 946 479 425 5.15 (4.94 to 5.36) 2344 455 260 65-69
3.97 (3.78 to 4.17) 1652 416 219 8.07 (7.79 to 8.36) 3135 388 396 70-74
7.03 (6.75 to 7.32) 2338 332 570 11.96 (11.57 to 12.35) 3668 306 809 75-79
12.47 (12.02 to 12.94) 2858 229 159 17.70 (17.14 to 18.28) 3695 208 730 80-85
1.37 (1.35 to 1.40) 9165 6 673 972 2.93 (2.89 to 2.98) 19 055 6 493 740 Total
Men:
0.05 (0.04 to 0.06) 45 929 528 0.45 (0.41 to 0.50) 412 916 590 30-34
0.08 (0.07 to 0.10) 77 924 254 0.45 (0.41 to 0.49) 409 911 311 35-39
0.09 (0.07 to 0.12) 76 821 559 0.44 (0.39 to 0.49) 355 809 997 40-44
0.15 (0.13 to 0.18) 116 760 068 0.55 (0.50 to 0.61) 412 749 353 45-49
0.22 (0.19 to 0.26) 163 739 153 0.67 (0.61 to 0.73) 489 729 014 50-54
0.31 (0.27 to 0.36) 189 611 878 0.74 (0.67 to 0.81) 445 603 892 55-59
0.43 (0.37 to 0.49) 218 507 598 0.98 (0.89 to 1.07) 489 500 299 60-64
0.79 (0.70 to 0.87) 333 423 791 1.42 (1.31 to 1.54) 595 417 588 65-69
1.67 (1.54 to 1.82) 545 325 637 2.69 (2.52 to 2.88) 865 321 199 70-74
2.84 (2.62 to 3.08) 621 218 448 4.03 (3.77 to 4.31) 868 215 248 75-79
5.42 (5.01 to 5.86) 640 118 005 7.01 (6.54 to 7.51) 814 116 096 80-85
0.47 (0.46 to 0.49) 3023 6 379 919 0.98 (0.95 to 1.00) 6153 6 290 586 Total
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RESEARCHTable 4| Discrimination and calibration performance data for QFractureScores in THIN cohort
THIN (complete case) External validation cohort (THIN) Internal validation cohort (QResearch)
Variables Men Women Men Women Men Women
Osteoporotic fracture:
37.04 (34.92 to
39.16)
48.93 (46.93 to
48.72)
37.99 (36.64 to
39.35)
49.24 (48.64 to
49.85)
30.02 (22.21 to
37.84)
44.87 (43.07 to
46.67)
R
2* (95% CI)
1.56 (1.50 to 1.64) 1.96 (1.92 to 2.00) 1.60 (1.56 to 1.65) 2.02 (1.99 to 2.04) 1.34 (1.09 to 1.59) 1.85 (1.78 to 1.91) D statistic† (95% CI)
0.742 0.810 0.739 0.816 0.688 (0.684 to
0.692)
0.788 (0.786 to
0.790)
Area under ROC
curve (95% CI)
0.012 (0.009 to
0.015)
0.029 (0.026 to
0.031)
0.010 (0.008 to
0.012)
0.027 (0.025 to
0.029)
Not calculated Not calculated Brier score‡ (95% CI)
Hip fracture:
57.41 (55.27 to
59.43)
62.19 (61.24 to
63.11)
60.42 (59.22 to
61.63)
62.82 (62.22 to
63.43)
63.19 (60.81 to
65.57)
63.94 (62.12 to
65.76)
R
2* (95% CI)
2.38 (2.28 to 2.48) 2.62 (2.57 to 2.68) 2.53 (2.46 to 2.59) 2.66 (2.63 to 2.70) 2.68 (2.55 to 2.82) 2.73 (2.62 to 2.83) D statistic† (95% CI)
0.843 0.884 0.855 0.890 0.856 (0.851 to
0.860)
0.890 (0.889 to
0.892)
Area under ROC
curve (95% CI)
0.006 (0.003 to
0.010)
0.014 (0.011 to
0.016)
0.005 (0.003 to
0.007)
0.013 (0.012 to
0.015)
Not calculated Not calculated Brier score‡ (95% CI)
ROC=receiver operating characteristic.
*Percentage of explained variation.
†Measure of discrimination.
‡Measure of prediction accuracy—that is, the average squared deviation between predicted and observed risk; a lower score represents greater accuracy.
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RESEARCHFigures
Fig 1 Observed versus predicted fracture risks for women. THIN=The Health Improvement Network
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;342:d3651 doi: 10.1136/bmj.d3651 Page 10 of 12
RESEARCHFig 2 Observed versus predicted fracture risks for men. THIN=The Health Improvement Network
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RESEARCHFig 3 Observed and predicted fracture risk by age group and sex
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